R&D
Starboard Value Criticizes Pfizer Leadership Over Underperforming R&D and Overpriced Acquisitions
Pfizer Inc., Starboard Value, Activist Investor, Pharmaceutical Industry, R&D Underperformance, Overpaid M&A Deals, Corporate Accountability
Johnson & Johnson Halts Phase II Dengue Study Amid Shift in R&D Priorities
Johnson & Johnson, Dengue Study, Phase II, Antiviral Drug, Mosnodenvir, Infectious Diseases, R&D Priorities
Flagship’s Winning Streak Continues with Singapore R&D Partnership
Flagship, R&D collaboration, Singapore, biotech, innovation
Eli Lilly Invests $4.5 Billion in Groundbreaking Indiana Manufacturing and R&D Facility
Eli Lilly, pharmaceutical manufacturing, R&D, Indiana, Lilly Medicine Foundry, clinical trials, drug development
Moderna Revamps R&D Strategy with $1.1B Cuts and Pipeline Overhaul
Moderna, R&D cuts, pipeline overhaul, biotechnology, pharmaceutical industry, cost reduction, research and development.
Repare Therapeutics Cuts 25% of Workforce, Preclinical Team Most Affected
Repare Therapeutics, layoffs, preclinical team, R&D prioritization, biotech industry
Aadi Bioscience Cuts 80% of R&D Staff Amid Fyarro Expansion Setbacks
Aadi Bioscience, R&D workforce, Fyarro, expansion efforts, layoffs, pharmaceutical industry
BioMarin Appoints New R&D and Business Development Leaders
BioMarin, R&D, Business Development, Leadership, Greg Friberg, James Sabry, Hank Fuchs
Genentech Closes Cancer Immunology Unit as Part of Broader R&D Restructuring
Genentech, Cancer Immunology, R&D Reprioritization, Roche, Cancer Research, Molecular Oncology
Incyte Discontinues Five Early-Stage Oncology Programs in Pipeline Refocus
Incyte, cancer pipeline, oncology programs, PD-L1 inhibitors, strategic review, R&D refocus